Trop-2 Inhibitors
2 drugsAbout Trop-2
Trop-2, or Tumor-associated calcium signal transducer 2, is a transmembrane glycoprotein often overexpressed in various cancer cells. Its overexpression makes it an attractive target for antibody-drug conjugates (ADCs) that deliver cytotoxic payloads directly to tumor cells.
Trop-2 is a significant oncology target, evidenced by two FDA-approved drugs, DATROWAY and TRODELVY. Currently, there is no genetic evidence directly linking Trop-2 to specific diseases, making target validation dependent on clinical data.
Trop-2 is targeted by two FDA-approved antibody-drug conjugates: DATROWAY (DAIICHI SANKYO) and TRODELVY (IMMUNOMEDICS). These drugs address oncology and other therapeutic areas, with approvals spanning from 2020 to 2025.
Top Trop-2 Drugs
The competitive landscape consists of two companies, DAIICHI SANKYO and IMMUNOMEDICS, with approved Trop-2 targeting drugs.
The concentrated market indicates high barriers to entry, requiring differentiated products or strategies.
Trop-2 Drug Modality Landscape
Modalities
Routes of Administration
Trop-2 requires biologic approaches (adc), likely due to its structure or location.
The exclusive focus on ADCs suggests a whitespace opportunity for novel modalities targeting Trop-2.
Trop-2 Clinical Trials 153 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Trop-2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 39 | 4 | 6 | 29 | 40% |
| Phase 2 | 84 | 2 | 8 | 74 | 20% |
| Phase 3 | 28 | 3 | 0 | 25 | 100% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
5 Phase 3 trials testing approved Trop-2 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Trop-2. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Trop-2 Drug Approval Timeline (2020 - 2025)
The approval timeline for Trop-2 targeting drugs spans 6 years, with TRODELVY approved in 2020 and DATROWAY in 2025.
Recent approval of DATROWAY suggests continued interest and potential for further drug development targeting Trop-2.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 81 (20 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Trop-2. A trial counts if an approved drug acting on Trop-2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.